Reagents and conditions; a) H2, aq. HCHO, PtO2/H2O-AcOH, 93%; b) SOCl2/allyl alcohol, quant.; c) MsCl, Et3N/THF, 77%; d) AcSH, Cs2CO3/dimethylacetamide, 70%; e) Pd(PPh3)4, PPh3, dimedone, 82%; f) PivCl, i-Pr2NEt/CH3CN then 13, i-Pr2NEt, 62%; g) NaOMe/MeOH then 1, i-Pr2NEt/DMF, 63%; h) H2, 7.5% Pd-C/THE-H2O then recrystallization from 61%. potent antibacterial activity compared with carbapenems 7a and 7b. In short, among the three kinds of amidine moiety (7a, 7b and 7d), the guanidine moiety gave the best result. However, although an elongation of the methylene chain of the 3-substituted pyrrolidine at the end of the side chain (7d, 7e, 7f and 7g) was effective in improving the antibacterial activity against Gram-negative bacteria, the urinary recovery of these derivatives dropped considerably.
Next, we carried out further modifications to increase the level of urinary recovery without decreasing the antibacterial activity. It was found that the introduction of a methyl group to the pyrrolidine moiety next to the carbapenem core raised the level of urinary recovery.24) Therefore, we introduced a methyl group on the nitrogen atom of the 3,5-disubstituted pyrrolidine moiety in the side chain. The results are shown in Table 2 . The antibacterial activity of all of the N-Me derivatives (8a-8g) against both Gram-positive and Gram-negative bacteria was maintained. Unfortunately, the antipseudomonal activity of carbapenems 8a-8g was 2-16 fold lower than that of N-H derivatives (7a-7g) and the increase in urinary recovery of carbapenems 8a-8g was also not satisfactory.
After many trials, we found that carbapenem derivatives with a 3-amino pyrrolidine moiety tethered by an amidino acetyl group at the end of the side chain improved urinary recovery. As shown in Table 3 , carbapenems 7h, 7i, 7l and 7m, which are derivatives with an amide functional group inserted at the end of the pyrrolidine side chain of 7c, 7e, 7f In the next stage, we carried out the synthesis of some N-Me derivatives of 7i for further improvement of urinary recovery without decreasing the antibacterial activity (Table  4 ). As shown in Table 4 , with respect to mono-or dimethylated derivatives 7n, 7o and 7p, the antibacterial activities and urinary recoveries were not improved.
However, it was revealed that carbapenem 8i, in which a methyl group was introduced into the pyrrolidine moiety of carbapenem 7i, showed excellent urinary recovery that was enough to make up for the disadvantage of the decrease in antipseudomonal activity and its antibacterial activity was superior to that of meropenem. Moreover, carbapenem 8i
showed not only a four-fold higher antibacterial activity against S. aureus 535 (MRSA), E, faecalis 681 and P. aeruginosa 3719, which are clinically important species, but also a two-fold higher urinary recovery than meropenem.
Next, our attention was focused on the antibacterial profile of stereoisomers of 8i (Table 5) . Surprisingly, the antibacterial activity of each of the isomers depended on the stereochemistry of the two pyrrolidine moieties in the side chain. In particular, the stereochemistry of the 3,5-disubstituted pyrrolidine moiety (particularly the 3-position) influenced the antibacterial activity. Among the isomers, although carbapenem 8q, which had a stereochemistry similar to 8i in regard to the 3,5-disubstituted pyrrolidine moiety and showed good antipseudomonal activity of 8q was slightly lower than that of 8i. The relationship between the urinary recovery and the stereochemistry of isomers was not clear.
The antibacterial activity of 8i, imipenem and meropenem against another series of Gram-positive and Gram-negative bacteria observed in the real clinical setting is listed in Table 6 . It was found that carbapenem 8i also showed potent antibacterial activity against these strains. In particular, it was revealed that the antibacterial activity of this compound against drug-resistant strains such as S. aureus 123-1 (MRSA), S. pneumoniae 10675 (PRSP) and three kinds of P. aeruginosa, was markedly higher than that of imipenem and meropenem.
The stability against hydrolysis by dehydropeptidase-I (DHP-I) of 8i, imipenem and meropenem was tested. As shown in General Methods IR spectra were recorded on a Jasco FT-IR 8300 or Jasco FT-IR 8900 spectrometer. NMR spectra were determined on a JEOL GX-270 (270MHz), GX-400 (400MHz) or Varian Mercury (400MHz) spectrometer using tetramethylsilane (TMS) or sodium 3-(trimethylsilyl)-propionate-d4 (TSP) as the internal standard. Mass spectra were recorded on JEOL HX-100, SX-102A or AX-505H mass spectrometer. Column chromatography was carried out on Silica gel 60 (Merck, Art. 9385), Silica gel 60N (Kanto Chemical, spherical, neutral) or Cosmosil 75C18 PREP (Nacalai Tesque).
To a solution of 9 (10.0g, 116mmol) in MeOH (50ml) was added a solution of Boc2O (20.3g, 92.9mmol) To a solution of (S)-3-chloroacetylamino-1-(tertbutoxycarbonyl)pyrrolidine (0.20g, 0.76mmol) in MeOH (4ml) were added NaI (0.34g, 2.28mmol) and 28% aqueous ammonia (4.0ml) and the resulting mixture was stirred at room temperature for 20 hours. The solvent was removed under reduced pressure and the resulting residue was diluted with aq. K2CO3 (10ml) and brine (10ml). The aqueous layer was extracted six times with CH2Cl2 (20ml).
The organic layer was dried over Na2SO4 and evaporated under reduced pressure to give 10 (0.16g, 87%) as an oil. Na2SO4 and evaporated under reduced pressure.
Recrystallization of the crude product from CH2Cl2 gave 11 (16.1g, 79%) as a solid. IR (KBr) cm-1 3424, 3269, 2976 , 1661 , 1571 , 1521 , 1352 , 1245 , 1067 , 1129 1H NMR J=8.7Hz), 8.22 (2H, d, J=8.7Hz) . MS (FAB) m/z 270
To a solution of 10 (0.12g, 0.50mmol) 
